Electromed: Contrarian 'Buy' With SmartVest

Electromed’s direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a long runway for greater HFCWO adoption. Hospital revenue is volatile, but the channel remains small, and full-year hospital sales still increased. The CEO transition retirement is another short-term variable, but long-term ELMD depends on favorable reimbursement and commercialization. So, after the recent selloff, I believe ELMD’s profitable growth and healthy balance sheet make the stock a viable "Buy" at these levels.

Electromed, Inc. ( ELMD ) sells niche medical devices that focus on respiratory care. Its overall business has been growing as more patients with chronic conditions such as bronchiectasis use its products to help clear mucus.